Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury

Coronary Artery Disease

Volumn 24, Issue 4, 2013, Pages 334-341

  Ke, Dan ^a   Fang, Jun ^a   Fan, Lin ^a   Chen, Zhaoyang ^a   Chen, Lianglong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Ischemia; Regulatory T cells; Reperfusion; Statin

Indexed keywords

MEVALONIC ACID; ROSUVASTATIN; TRANSCRIPTION FACTOR FOXP3; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE INJURY; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIPID BLOOD LEVEL; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; WESTERN BLOTTING;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; FLUOROBENZENES; FORKHEAD TRANSCRIPTION FACTORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEVALONIC ACID; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES; T-LYMPHOCYTES, REGULATORY; TROPONIN I;

EID: 84877085500     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283608c12     Document Type: Article

References (28)

1. Vinten JJ. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61:481-497.
2. Halloran PF, Autenried P, Ramassar V, Cockfield S. Local T cell responses induce widespread MHC expression: evidence that IFN-g induces its own expression in remote sites. J Immunol 1992; 148:3837-3846.
3. Svendsen JH, Hansen PR, Ali S, Baandrup U, Haunsø S. Leucocyte depletion attenuates the early increase in myocardial capillary permeability to small hydrophilic solutes following ischaemia and reperfusion. Cardiovasc Res 1993; 27:1288-1294.
4. Gao XM, Liu Y,White D, Drew BG, Bruce CR, Kiriazis H, et al. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. J Mol Cell Cardiol 2011; 50:991-999.
5. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006; 114:2056-2064.
6. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83:1113-1151.
7. Jneid H, Leessar M, Bolli R. Cardiac preconditioning during percutaneous coronary interventions. Cardiovasc Drugs Ther 2005; 19:211-217.
8. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, M Endres. Rosuvastatin: a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942:23-30.
9. Merla R, Daher IN, Ye Y, Uretsky BF, Birnbaum Y. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J 2007; 154:391-402.
10. Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real? Vasc Health Risk Manag 2007; 3:611-613.
11. Buckner JH, Ziegler SF. Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res Ther 2004; 6: 215-222.
12. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008; 28:546-558.
13. Burne-Taney MJ, Liu M, Baldwin WM, Racusen L, Rabb H. Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol 2006; 176:7015-7020.
14. Arias-Diaz J, Ildefonso JA, Mun oz JJ, Zapata A, Jimenez E. Both tacrolimus and sirolimus decrease Th1/Th2 ratio, and increase regulatory T lymphocytes in the liver after ischemia/reperfusion. Lab Invest 2009; 89:433-445.
15. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, George J. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+T cells. Atherosclerosis 2008; 197: 829-839.
16. Mira E, Leon B, Barber DF, Jimenez-Baranda S, Goya I, Almonacid L, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008; 181:3524-3534.
17. Fang J, Chen L,Wu L, Li W. Intra-cardiac remote ischemic post-conditioning attenuates ischemia-reperfusion injury in rats. Scand Cardiovasc J 2009; 43:386-394.
18. Massey KD, Strieter RM, Kunkel SL, Danforth JM, Standiford TJ. Cardiac myocytes release leukocyte-stimulating factors. Am J Physiol 1995; 269:980-987.
19. Frangogiannis NG. The role of the chemokines in myocardial ischemia and reperfusion. Curr Vasc Pharmacol 2004; 2:163-174.
20. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003; 93:98-103.
21. Correia LC, Sposito AC, Lima JC, Magalhaes LP, Passos LC, Rocha MS. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2003; 92:298-301.
22. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 2003; 285:59-64.
23. Landsberger M, Jantzen F, Konemann S, Felix SB. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Biochem Biophys Res Commun 2005; 336:1005-1009.
24. Peng X. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol 2006; 178:130-139.
25. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336.
26. Mausner FK, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+T cells. Atherosclerosis 2008; 197:829-839.
27. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6:358-370.
28. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203:401-412.